<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Approach to the patient with large gastric folds
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Approach to the patient with large gastric folds
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Approach to the patient with large gastric folds
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Pamela J Jensen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Thomas Lamont, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enlarged or giant mucosal folds in the stomach (diffuse mucosal hypertrophy) are attributable to a variety of proliferative, inflammatory, and infiltrative conditions of the stomach. These conditions may primarily involve the mucosa, submucosa, or both but have a similar endoscopic appearance, and the underlying etiology cannot be determined without additional evaluation. This topic reviews the epidemiology, etiology, and evaluation of large gastric folds.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The normal gastric mucosa is composed of two compartments: the superficial mucosa, which includes the surface mucous cells and foveolar cells, and the deep compartment, which is composed of the specialized epithelium [
         <a href="#rid1">
          1
         </a>
         ]. Surface cells and foveolar cells line the upper portion of the gastric glands. Slightly deeper in the gland is the isthmus, which contains the mucous neck cells. The base of the oxyntic gland contains the specialized epithelium, which includes the enterochromaffin cell (serotonin), the enterochromaffin-like cell (histamine), the chief cell (pepsinogen), the D cell (somatostatin), and the parietal cell (acid and intrinsic factor).
        </p>
        <p>
         Enlarged or giant gastric folds are due to diffuse mucosal hypertrophy, which may be due to a hyperplastic or nonhyperplastic gastropathy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperplastic gastropathy – The gastric epithelial cells that compose the oxyntic glands become hyperplastic and give rise to giant mucosal folds. Hyperplastic gastropathies include Ménétrier's disease and its rare variant, hyperplastic hypersecretory gastropathy, and Zollinger-Ellison syndrome. (See
         <a class="local">
          'Hyperplastic gastropathies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonhyperplastic gastropathy – The gastric mucosa may contain other (non-intrinsic) cell types that result in enlargement of the gastric folds. Nonhyperplastic gastropathy may be due to
         <em>
          Helicobacter pylori
         </em>
         gastritis, infiltrative diseases, infections, and malignancy. (See
         <a class="local">
          'Nonhyperplastic gastropathies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         In one series, endoscopic snare biopsy was performed in 52 patients with large gastric folds (greater than 1.0 cm in width and persisting after air insufflation) [
         <a href="#rid2">
          2
         </a>
         ]. The diagnoses included the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic gastritis/lymphoid hyperplasia – 40 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benign tumors – 16 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric malignancy (adenocarcinoma, B cell lymphoma) – 12 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Zollinger-Ellison syndrome – 10 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ménétrier's disease – 8 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2105610850">
         <span class="h1">
          ETIOLOGY OF ENLARGED GASTRIC FOLDS
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Hyperplastic gastropathies
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Ménétrier's disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ménétrier's disease (also called protein-losing hypertrophic gastropathy) is a rare acquired condition of the stomach that is characterized by the following features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Giant mucosal folds in the gastric fundus and body (
         <a class="graphic graphic_picture graphicRef63252" href="/z/d/graphic/63252.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diminished acid secretory capacity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A protein-losing state resulting in hypoalbuminemia
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H211542375">
         <span class="h4">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ménétrier's disease is most common in middle-aged males and cases have been reported in both adults and in children. In contrast to children, Ménétrier's disease is usually progressive in adults. There are rare reports of spontaneous regression in adults, and virtually none in adults with symptoms longer than six months' duration [
         <a href="#rid3">
          3
         </a>
         ]. An association with ulcerative colitis has been reported [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h4">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of Ménétrier's disease is not well understood. It is thought to involve increased signaling of the epidermal growth factor receptor (EGFR), which results in proliferation of epithelial cells of the surface mucous cell compartment [
         <a href="#rid1">
          1,5-7
         </a>
         ]. The enhanced signaling of EGFR in Ménétrier's disease is driven by overproduction of transforming growth factor-alpha (TGF-alpha), a ligand that can bind and activate EGFR. TGF-alpha is produced by the oxyntic mucosa, predominantly by the parietal cells; however, the molecular defect that results in the localized upregulation of TGF-alpha is not known [
         <a href="#rid1">
          1,6,7
         </a>
         ]. TGF-alpha is known to stimulate growth of epithelial cells and to inhibit gastric acid secretion. The decreased acid production may be due to both direct effects on the parietal cells and indirectly via stimulation of somatostatin release.
        </p>
        <p>
         Gastric infection with cytomegalovirus (CMV) is postulated to be an important cause of Ménétrier's disease in children. One-third of the children with Ménétrier's reportedly have CMV-associated Ménétrier's disease, which usually spontaneously resolves in two to four weeks. It has been difficult to prove that an actual infection with CMV is present in these pediatric cases due to the high prevalence of CMV infection in children. CMV may infect epithelial cells by interacting with EGFR, thereby activating a tyrosine kinase, a requirement for viral particle entry [
         <a href="#rid8">
          8,9
         </a>
         ]. TGF-alpha was found to be increased by immunohistochemistry in one childhood and one adult case of CMV-associated Ménétrier's disease [
         <a href="#rid8">
          8,10
         </a>
         ]. As CMV is cleared from the stomach, the stimulus to the EGFR is decreased, thus resulting in less TGF-alpha production, lessened cell proliferation, and a return to normal anatomy.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h4">
          Clinical manifestations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Signs and symptoms
         </strong>
         – Patients with Ménétrier's disease can present with a variety of clinical features including epigastric pain, nausea, vomiting, diarrhea, weight loss, and more rarely, gastrointestinal bleeding [
         <a href="#rid11">
          11-14
         </a>
         ]. In addition, patients with Ménétrier's disease also have manifestations of protein-losing gastroenteropathy. These include peripheral edema, ascites, pleural and pericardial effusions. Patients with the hypertrophic, hypersecretory variant of Ménétrier's disease may have peptic ulcers due to high rates of gastric acid secretion. Otherwise, the clinical features are similar to the more common form of Ménétrier's disease [
         <a href="#rid13">
          13,15-19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">
          "Protein-losing gastroenteropathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one series of 40 patients, the main complaints were epigastric pain (65 percent), weakness (60 percent), anorexia (45 percent), weight loss (45 percent), edema (38 percent), and vomiting (38 percent) [
         <a href="#rid14">
          14
         </a>
         ]. In addition, approximately 80 percent of patients had hypoalbuminemia and increased enteric protein loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory findings
         </strong>
         – Hypoalbuminemia is present in 20 to 100 percent of patients with Ménétrier's disease [
         <a href="#rid11">
          11-13,20,21
         </a>
         ]. Other laboratory abnormalities include lymphopenia, hypochlorhydria, and reduced serum levels of globulins, cholesterol, alpha-1 antitrypsin, fibrinogen, and ceruloplasmin; these reductions are similar to patients with other forms of protein-losing gastroenteropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Small to moderate elevation of serum gastrin levels may be present [
         <a href="#rid22">
          22
         </a>
         ]. Intragastric pH is usually high (median pH of 6). Basal and stimulated gastric acid secretion is usually low or normal in Ménétrier's disease, but varies depending upon the point in the disease course when such measurements are made [
         <a href="#rid11">
          11,13,21,23
         </a>
         ]. Patients with the rare hypertrophic, hypersecretory variant of Ménétrier's disease have elevated gastric acid secretion without significant hypergastrinemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h4">
          Cancer risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         There may be an increased risk of gastric neoplasia (dysplasia or adenocarcinoma) in patients with Ménétrier's disease. However, there are few studies that have evaluated the risk of gastric cancer in Ménétrier's disease [
         <a href="#rid24">
          24
         </a>
         ]. Risk estimates vary from 2 to 15 percent [
         <a href="#rid11">
          11,13,21,25-27
         </a>
         ]. In many studies that have reported an increased risk of gastric cancer in patients with Ménétrier's disease, adequate histologic confirmation of the two conditions is lacking.
        </p>
        <p class="headingAnchor" id="H1417276834">
         <span class="h3">
          Zollinger-Ellison syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Zollinger-Ellison syndrome (gastric acid hypersecretion due to hypergastrinemia from a gastrinoma, either sporadic or as a component of multiple endocrine neoplasia type 1 [MEN1]) is a hyperplastic gastropathy involving the body and fundus of the stomach. One hyperplastic cell type in Zollinger-Ellison syndrome is the parietal cell that results in the hypersecretion of gastric acid. The high levels of circulating gastrin seen in patients with gastrinoma lead to parietal cell hyperplasia via increased expression of parathyroid hormone-related peptide (PTHrP), also known as parathyroid hormone-like hormone (PTHLH), expression by parietal cells [
         <a href="#rid28">
          28
         </a>
         ]. There is also an increase in histamine-secreting enterochromaffin-like cells, as gastrin is trophic for these cells. (See
         <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">
          "Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3570677208">
         <span class="h2">
          Nonhyperplastic gastropathies
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Helicobacter pylori gastritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute gastritis due to
         <em>
          H. pylori
         </em>
         can be associated with striking acute inflammation and enlarged gastric folds, giving the impression of a gastric malignancy [
         <a href="#rid29">
          29
         </a>
         ]. Chronic
         <em>
          H. pylori
         </em>
         gastritis may also be associated with enlarged gastric folds [
         <a href="#rid30">
          30,31
         </a>
         ]. In a report of 48 patients biopsied with isolated thickened gastric folds, chronic active gastritis was identified most frequently on biopsy (81 percent), with evidence of
         <em>
          H. pylori
         </em>
         in 92 percent of those biopsied [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/31.html" rel="external">
          "Acute and chronic gastritis due to Helicobacter pylori"
         </a>
         .)
        </p>
        <p>
         Other observations have suggested an association between
         <em>
          H. pylori
         </em>
         gastritis and enlarged gastric folds [
         <a href="#rid15">
          15-17,33-36
         </a>
         ]. In one such series, 18 of 32 patients with thickened gastric folds were infected with
         <em>
          H. pylori
         </em>
         [
         <a href="#rid34">
          34
         </a>
         ].
         <em>
          H. pylori
         </em>
         eradication therapy led to normalization of gastric fold size.
        </p>
        <p>
         The pathogenesis of diffuse mucosal hypertrophy in
         <em>
          H. pylori
         </em>
         gastritis is uncertain. One case report suggested that production of an enteroendocrine mucosal growth factor, glucagon-like peptide (GLP)-2, is upregulated in
         <em>
          H. pylori
         </em>
         infection. It is hypothesized that the increase in this trophic hormone may result in the formation of giant folds, which then recede along with the serum GLP-2 levels with resolution of infection [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Another study demonstrated different levels of cytokine production associated with different strains of
         <em>
          H. pylori
         </em>
         [
         <a href="#rid38">
          38
         </a>
         ]. They found that the
         <em>
          H. pylori
         </em>
         isolated from a patient with Ménétrier's disease induced the production of high levels of hepatocyte growth factor (HGF) mRNA expression. HGF has been reported to alter the tight junctions of gastric epithelial cells, which would lead to protein loss.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Gastric neoplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neoplasms, particularly adenocarcinoma and lymphoma or even lymphoblastic leukemia [
         <a href="#rid39">
          39
         </a>
         ], and carcinoid tumors, should be excluded in patients with enlarged gastric folds [
         <a href="#rid2">
          2
         </a>
         ]. Endoscopic ultrasonography may be helpful in this setting [
         <a href="#rid40">
          40,41
         </a>
         ]; however, a biopsy is needed to make the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">
          "Clinical presentation and diagnosis of primary gastrointestinal lymphomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2513.html" rel="external">
          "Clinical features, diagnosis, and staging of gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">
          "Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Other causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other diseases that may be associated with large gastric folds include lymphocytic gastritis (
         <a class="graphic graphic_picture graphicRef66689" href="/z/d/graphic/66689.html" rel="external">
          picture 2
         </a>
         ) (which may be related in some cases to
         <em>
          H. pylori
         </em>
         [
         <a href="#rid33">
          33,42
         </a>
         ]), sarcoidosis, eosinophilic gastroenteritis, HIV-associated hypertrophic gastritis, and very rarely, Cronkhite-Canada syndrome [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">
          "Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">
          "Eosinophilic gastrointestinal diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">
          "Overview of colon polyps"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1034852796">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H2756471574">
         <span class="h2">
          History and examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient's medical history and physical examination may provide valuable clues as to the possible etiology of enlarged gastric folds. For example, patients with pronounced constitutional symptoms (eg, persistent fevers, night sweats, weight loss, fatigue) should be evaluated for systemic diseases such as gastric lymphoma. Patients with Cronkhite-Canada syndrome have alopecia, cutaneous hyperpigmentation, gastrointestinal polyposis, onychodystrophy, diarrhea, weight loss, and abdominal pain. Patients with Zollinger-Ellison syndrome have a history of multiple or refractory peptic ulcers; ulcers distal to the duodenum; peptic ulcer disease and diarrhea; or multiple endocrine neoplasia type 1 (MEN1). (See
         <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">
          "Overview of colon polyps", section on 'Cronkhite-Canada syndrome'
         </a>
         .)
        </p>
        <p>
         In some cases, the presence of an underlying condition is already known (eg,
         <em>
          H. pylori
         </em>
         , sarcoidosis, or eosinophilic gastroenteritis).
        </p>
        <p class="headingAnchor" id="H2825391989">
         <span class="h2">
          Upper endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The underlying etiology cannot be determined without additional evaluation (eg, gastric biopsy). In patients with Ménétrier's disease, the enlarged folds are usually confined to the oxyntic mucosa (body and fundus), with sparing of the antrum (
         <a class="graphic graphic_picture graphicRef63252" href="/z/d/graphic/63252.html" rel="external">
          picture 1
         </a>
         ), and may reach several centimeters in thickness. Although gastric folds are usually enlarged symmetrically, the appearance may be asymmetric and polypoid. Gastric rugal folds may fill the lumen, and often have surface erosions, and are accompanied by copious amounts of thick mucus that may form bridges across the gastric lumen and obscure visualization.
        </p>
        <p>
         Patients with Zollinger-Ellison syndrome and eosinophilic gastroenteritis may have concurrent ulcers in the stomach or small intestine. The endoscopic appearance of polyposis syndromes (familial adenomatous polyposis, Peutz-Jeghers syndrome) and, rarely, proton pump inhibitor-induced fundal gland polyposis can mimic Ménétrier's disease when polyposis is profuse [
         <a href="#rid44">
          44,45
         </a>
         ]. However, these are distinguished by histology. (See
         <a class="medical medical_review" href="/z/d/html/2518.html" rel="external">
          "Gastric polyps"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2593.html" rel="external">
          "Clinical manifestations and diagnosis of familial adenomatous polyposis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">
          "Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
         Rarely, gastric varices in the fundus can give the appearance of enlarged folds on imaging or on upper endoscopy. If gastric varices are suspected, gastric biopsies should be avoided, and endoscopic ultrasonography should be performed to distinguish between the two [
         <a href="#rid46">
          46
         </a>
         ]. Varices are round anechoic structures arising from the lamina propria or submucosa. Benign causes
         <strong>
         </strong>
         of giant gastric folds
         <strong>
         </strong>
         (eg, gastritis) tend to thicken the second and third of the five layers of the stomach, whereas malignancies tend to involve the fourth layer. Gastric lymphoma may be hypoechoic, whereas gastric adenocarcinoma can show thick noncompressible folds [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2666.html" rel="external">
          "Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract", section on 'Varices'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1649870294">
         <span class="h3">
          Gastric biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Determining the etiology of large gastric folds is often possible based on histopathology. A full-thickness gastric biopsy (or endoscopic snare or suction biopsy) is usually required to evaluate for the loss of the deep glandular component [
         <a href="#rid21">
          21,47
         </a>
         ]. The diagnosis of Ménétrier's disease is established on biopsy by the demonstration of extreme foveolar hyperplasia with glandular atrophy, involving loss of parietal and chief cells. Ménétrier's disease usually is associated with a marked reduction in parietal cell mass. The diagnosis of gastric sarcoidosis rests upon histologic evidence of non-necrotizing granulomas in the biopsy specimens, exclusion of other causes of granulomatous inflammation (eg, some infections), and clinical and pathologic evidence of sarcoidosis affecting other organ systems. Additional stains for
         <em>
          H. pylori
         </em>
         and cytomegalovirus should be performed to rule out concurrent infection.
        </p>
        <p class="headingAnchor" id="H3382110466">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with Zollinger-Ellison syndrome, a serum gastrin value greater than 10 times the upper limit of normal (1000 pg/mL) in the presence of a gastric pH below 2 is diagnostic. In patients with Ménétrier's disease, intragastric pH is usually high and small to moderate elevation of fasting serum gastrin levels may be present [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         We also obtain a complete blood count to evaluate for anemia and total protein and serum albumin levels to screen for a protein-losing enteropathy. In patients with edema and hypoalbuminemia, additional evaluation to confirm the presence of a protein-losing gastroenteropathy is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">
          "Protein-losing gastroenteropathy", section on 'Laboratory studies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1826783026">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H968250119">
         <span class="h2">
          Treatment of underlying diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of management is to treat the underlying disease. The treatments used for specific disorders are described in detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Zollinger-Ellison (See
         <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">
          "Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoidosis (See
         <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">
          "Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Gastric'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eosinophilic gastroenteritis (See
         <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">
          "Eosinophilic gastrointestinal diseases", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cronkhite-Canada syndrome (See
         <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">
          "Overview of colon polyps", section on 'Cronkhite-Canada syndrome'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphocytic gastritis (See
         <a class="medical medical_review" href="/z/d/html/29.html" rel="external">
          "Gastritis: Etiology and diagnosis", section on 'Etiology and classification'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          H. pylori
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3786209173">
         <span class="h2">
          Ménétrier's disease
         </span>
        </p>
        <p class="headingAnchor" id="H631439151">
         <span class="h3">
          Initial management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of Ménétrier's disease is challenging and the best approach to treatment is unclear. Randomized controlled trials are lacking and data on treatment efficacy are limited to small case series and case reports.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General measures
         </strong>
         – Supportive care in patients with a protein-losing enteropathy is with a low-fat, high-protein, high medium-chain triglyceride diet to reduce protein loss. The diet should be low in long-chain fatty acids, generally present as long-chain triglycerides. (See
         <a class="medical medical_review" href="/z/d/html/4769.html" rel="external">
          "Protein-losing gastroenteropathy", section on 'Dietary therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with evidence of cytomegalovirus or
         <em>
          H. pylori
         </em>
         infections on gastric biopsy should undergo treatment. Treatment of these infections has been associated with resolution of Ménétrier's disease in case reports [
         <a href="#rid33">
          33-36,42,48-50
         </a>
         ]. (See
         <a class="local">
          'Helicobacter pylori gastritis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Organ-specific complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of gastrointestinal bleeding in patients with Ménétrier's disease is similar to other causes of GI bleeding and is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastric antisecretory agents
         </strong>
         – In patients with persistent symptoms despite supportive measures, we perform a one- to three-month trial of an antisecretory agent (histamine 2 receptor antagonist or proton pump inhibitor) in order to reduce gastric acid secretion and gastric protein loss while monitoring the patient for a reduction in symptoms and signs (eg, edema) and improvement in serum protein levels. However, studies supporting the effectiveness of these agents are lacking.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3287836601">
         <span class="h3">
          Persistent symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited data to guide treatment in patients with persistent symptoms despite antisecretory therapy, and the choice of treatment is based on the nature and severity of symptoms, ease of administration, individual preference, and insurance considerations.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          Octreotide
         </a>
         – Multiple case reports of the use of octreotide, a somatostatin analogue, for 3 to 12 months in patients with Ménétrier's disease suggest that its use is associated with improvement of serum protein levels and in clinical symptoms [
         <a href="#rid51">
          51-54
         </a>
         ]. Molecular evidence suggests that octreotide may reduce epidermal growth factor receptor (EGFR) signaling downstream [
         <a href="#rid7">
          7
         </a>
         ]. However, octreotide does not appear to consistently reverse the underlying gastric rugal hypertrophy, and long-term outcome data are lacking [
         <a href="#rid53">
          53-55
         </a>
         ]. In addition, octreotide and its analogues require subcutaneous administration. Although an oral preparation is now available, it has not been evaluated in patients with Ménétrier's disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          Cetuximab
         </a>
         – Cetuximab is a monoclonal antibody to EGFR that has been used to treat Ménétrier's disease. In one case series that included nine patients with Ménétrier's disease, seven patients completed treatment with cetuximab for one month [
         <a href="#rid4">
          4
         </a>
         ]. All seven patients demonstrated statistically significant improvement in quality-of-life indices as well as in biochemical measures (gastric acidity). Four patients also had almost complete reversal of foveolar hyperplasia. However, four of the seven eventually required total gastrectomy [
         <a href="#rid4">
          4
         </a>
         ]. In another case series of two patients who were treated for four months and one year, respectively, both had resolution of symptoms while on treatment with cetuximab [
         <a href="#rid56">
          56
         </a>
         ]. In the United States, the Food and Drug Administration (FDA) has allowed cetuximab to be used on a compassionate need basis in some patients with Ménétrier's disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrectomy
         </strong>
         – Gastrectomy is reserved for those patients with intractable symptoms and signs refractory to medical therapy. In rare cases with massive or unrelenting bleeding that is uncontrollable endoscopically, gastrectomy is required. Even though Ménétrier's disease is primarily a disease of the gastric fundus and body, a total gastrectomy is the surgery of choice due to fewer surgical complications and better quality of life as compared with partial proximal gastrectomy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1759256821">
         <span class="h3">
          Gastric cancer screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with Ménétrier's disease who have not undergone gastrectomy, we perform endoscopic surveillance every one to two years for early detection of dysplasia or carcinoma [
         <a href="#rid8">
          8,57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enlarged or giant mucosal folds in the stomach (diffuse mucosal hypertrophy) are attributable to a variety of proliferative, inflammatory, and infiltrative conditions of the stomach, which can cause a hyperplastic or nonhyperplastic gastropathy. In hyperplastic gastropathies, gastric epithelial cells that compose the oxyntic glands become hyperplastic and give rise to giant mucosal folds. Hyperplastic gastropathies include Ménétrier's disease and its rare variant, hyperplastic hypersecretory gastropathy, and Zollinger-Ellison syndrome. Large gastric folds are associated with other non-hyperplastic gastropathies including infections (eg,
         <em>
          H. pylori
         </em>
         , cytomegalovirus [CMV]), infiltrative diseases, and neoplasms. (See
         <a class="local">
          'Histopathology'
         </a>
         above and
         <a class="local">
          'Etiology of enlarged gastric folds'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ménétrier's disease is a rare acquired condition of the stomach. Patients with Ménétrier's disease can present with a variety of clinical features including epigastric pain, weight loss, nausea, vomiting, diarrhea, peripheral edema due to protein-losing gastroenteropathy, and gastrointestinal bleeding. (See
         <a class="local">
          'Ménétrier's disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The underlying etiology of large gastric folds cannot be determined based on endoscopic imaging alone. Although the patient's medical history and physical examination may provide valuable clues as to the underlying etiology of enlarged gastric folds, a full-thickness gastric biopsy (or endoscopic snare or suction biopsy) is usually required. The diagnosis of Ménétrier's disease is established by a deep gastric biopsy showing extreme foveolar hyperplasia with glandular atrophy in a patient with striking enlargement of gastric folds or rugae seen on endoscopy or abdominal imaging. (See
         <a class="local">
          'Upper endoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with large gastric folds, we also obtain a complete blood count to evaluate for anemia and total protein and serum albumin levels to screen for a protein-losing enteropathy. (See
         <a class="local">
          'Laboratory tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mainstay of management is to treat the underlying disease. The treatment of Ménétrier's disease is challenging and the best approach to treatment is unclear. (See
         <a class="local">
          'Ménétrier's disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In addition to a low-fat, high-protein, high medium-chain triglyceride diet to reduce protein loss, initial management includes treatment of
         <em>
          H. pylori
         </em>
         or CMV infection, if present, and a one- to three-month trial of acid suppressive therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with persistent symptoms in spite of antisecretory therapy, options include
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         or
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , an epidermal growth factor receptor inhibitor. However, data on the efficacy of both options are limited in this population.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gastrectomy is reserved for those patients with intractable symptoms and signs refractory to medical therapy. In rare cases with massive or unrelenting bleeding that is uncontrollable endoscopically, gastrectomy is required. (See
         <a class="local">
          'Ménétrier's disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with Ménétrier's disease who have not had total gastrectomy, we perform endoscopic surveillance every one to two years because of the possible increase in risk of gastric cancer. (See
         <a class="local">
          'Cancer risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H91878801">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Beverly Dickson, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Toubia N, Schubert ML. Menetrier's Disease. Curr Treat Options Gastroenterol 2008; 11:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komorowski RA, Caya JG, Geenen JE. The morphologic spectrum of large gastric folds: utility of the snare biopsy. Gastrointest Endosc 1986; 32:190.
          </a>
         </li>
         <li class="breakAll">
          Riddell R, Jain D. Stomach and proximal duodenum: inflammatory and miscellaneous disorders. In: Lewin, Weinstein and Riddell's Gastrointestinal Pathology and its Clinical Implications, 2nd ed, Bernstein C, Guha S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. p.590.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiske WH, Tanksley J, Nam KT, et al. Efficacy of cetuximab in the treatment of Menetrier's disease. Sci Transl Med 2009; 1:8ra18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dempsey PJ, Goldenring JR, Soroka CJ, et al. Possible role of transforming growth factor alpha in the pathogenesis of Ménétrier's disease: supportive evidence form humans and transgenic mice. Gastroenterology 1992; 103:1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coffey RJ, Washington MK, Corless CL, Heinrich MC. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J Clin Invest 2007; 117:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothenberg M, Pai R, Stuart K. Successful use of octreotide to treat Ménétrier's disease: a rare cause of abdominal pain, weight loss, edema, and hypoalbuminemia. Dig Dis Sci 2009; 54:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nalle SC, Turner JR. Menetrier's disease therapy: rebooting mucosal signaling. Sci Transl Med 2009; 1:8ps10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Huong SM, Chiu ML, et al. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003; 424:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sferra TJ, Pawel BR, Qualman SJ, Li BU. Ménétrier disease of childhood: role of cytomegalovirus and transforming growth factor alpha. J Pediatr 1996; 128:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scharschmidt BF. The natural history of hypertrophic gastrophy (Menetrier's disease). Report of a case with 16 year follow-up and review of 120 cases from the literature. Am J Med 1977; 63:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Searcy RM, Malagelada JR. Ménétrièr's disease and idiopathic hypertrophic gastropathy. Ann Intern Med 1984; 100:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fieber SS, Rickert RR. Hyperplastic Gastropathy. Analysis of 50 selected cases from 1955-1980. Am J Gastroenterol 1981; 76:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meuwissen SG, Ridwan BU, Hasper HJ, Innemee G. Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch Ménétrier Study Group. Scand J Gastroenterol Suppl 1992; 194:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           STEMPIEN SJ, DAGRADI AE, REINGOLD IM, et al. HYPERTROPHIC HYPERSECRETORY GASTROPATHY. ANALYSIS OF 15 CASES AND A REVIEW OF THE PERTINENT LITERATURE. Am J Dig Dis 1964; 9:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan DT, Stempien SJ, Dagradi AE. The clinical spectrum of hypertrophic hypersecretory gastropathy. Report of 50 patients. Gastrointest Endosc 1971; 18:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simson JN. Hyperplastic gastropathy. Br Med J (Clin Res Ed) 1985; 291:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overholt BF, Jeffries GH. Hypertrophic, hypersecretory protein-losing gastropathy. Gastroenterology 1970; 58:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks AM, Isenberg J, Goldstein H. Giant thickening of the gastric mucosa with acid hypersecretion and protein-losing gastropathy. Gastroenterology 1970; 58:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly DG, Miller LJ, Malagelada JR, et al. Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982; 83:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundt TM 3rd, Compton CC, Malt RA. Ménétrier's disease. A trivalent gastropathy. Ann Surg 1988; 208:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komorowski RA, Caya JG. Hyperplastic gastropathy. Clinicopathologic correlation. Am J Surg Pathol 1991; 15:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry EM, Ben-Dov Y, Freund U. Spontaneous remission of protein-losing gastropathy associated with Menetrier's disease. A plea for conservative management. Arch Intern Med 1980; 140:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spengel K, Olyaee M, Fan F. Pathologic quiz case: a 39-year-old woman with nausea, vomiting, diarrhea, and weight loss. Ménétrier disease. Arch Pathol Lab Med 2005; 129:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CHUSID EL, HIRSCH RL, COLCHER H. SPECTRUM OF HYPERTROPHIC GASTROPATHY; GIANT RUGAL FOLDS, POLYPOSIS, AND CARCINOMA OF THE STOMACH--CASE REPORT AND REVIEW OF THE LITERATURE. Arch Intern Med 1964; 114:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood MG, Bates C, Brown RC, Losowsky MS. Intramucosal carcinoma of the gastric antrum complicating Menetrier's disease. J Clin Pathol 1983; 36:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almazar AE, Penfield JD, Saito YA, Talley NJ. Survival Times of Patients With Menetrier's Disease and Risk of Gastric Cancer. Clin Gastroenterol Hepatol 2021; 19:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Menhali A, Keeley TM, Demitrack ES, Samuelson LC. Gastrin induces parathyroid hormone-like hormone expression in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol 2017; 312:G649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Chen J, Guo Y, et al. The expression of PTHLH in human gastric mucosa enterochromaffin-like cells. Dig Dis Sci 2011; 56:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herz R, Lombardi E, Wipping F, Stolte M. [Helicobacter pylori-associated hypertrophic gastritis. Imitation of Ménétrier disease]. Fortschr Med 1992; 110:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stolte M, Bätz C, Eidt S. Giant fold gastritis--a special form of Helicobacter pylori associated gastritis. Z Gastroenterol 1993; 31:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran T, Hung P, Laucirica R, et al. The clinical significance of thickened gastric folds found on upper gastrointestinal series. J Clin Gastroenterol 2002; 35:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groisman GM, George J, Berman D, Harpaz N. Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. Am J Gastroenterol 1994; 89:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawasaki M, Hizawa K, Aoyagi K, et al. Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. Am J Gastroenterol 1997; 92:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayerdörffer E, Ritter MM, Hatz R, et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in Ménétrier's disease? Gut 1994; 35:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada M, Sumazaki R, Adachi H, et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe K, Beinborn M, Nagamatsu S, et al. Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity. Scand J Gastroenterol 2005; 40:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishikawa T, Ando T, Obayashi H, et al. Helicobacter pylori isolated from a patient with Ménétrier's disease increases hepatocyte growth factor mRNA expression in gastric fibroblasts: comparison with Helicobacter pylori isolated from other gastric diseases. Dig Dis Sci 2008; 53:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouda A, Kamath B, Chung C, Punnett A. Menetrier's disease (protein-losing gastropathy) in a child with acute lymphoblastic leukemia. Int J Pediatr Adolesc Med 2019; 6:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginès A, Pellise M, Fernández-Esparrach G, et al. Endoscopic ultrasonography in patients with large gastric folds at endoscopy and biopsies negative for malignancy: predictors of malignant disease and clinical impact. Am J Gastroenterol 2006; 101:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okanobu H, Hata J, Haruma K, et al. Giant gastric folds: differential diagnosis at US. Radiology 2003; 226:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madisch A, Miehlke S, Neuber F, et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006; 23:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kindblom LG, Angervall L, Santesson B, Selander S. Cronkhite-Canada syndrome. Case report. Cancer 1977; 39:2651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parks T, Ragland KL, Steiner MA, et al. Ménétrier Mimicker Complicating Ulcerative Colitis: Proton-Pump Inhibitor-Induced Hyperplastic Polyps. J Pediatr 2015; 167:776.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rich A, Toro TZ, Tanksley J, et al. Distinguishing Ménétrier's disease from its mimics. Gut 2010; 59:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen TK, Wu CH, Lee CL, et al. Endoscopic ultrasonography in the differential diagnosis of giant gastric folds. J Formos Med Assoc 1999; 98:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfsen HC, Carpenter HA, Talley NJ. Menetrier's disease: a form of hypertrophic gastropathy or gastritis? Gastroenterology 1993; 104:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffer V, Finkelstein Y, Balter J, et al. Ganciclovir treatment in Ménétrier's disease. Acta Paediatr 2003; 92:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wald A, Frenkel LM, Benjamin DL, Christie DL. Cytomegalovirus gastropathy in a child: resolution after ganciclovir therapy. Clin Infect Dis 1998; 26:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badov D, Lambert JR, Finlay M, Balazs ND. Helicobacter pylori as a pathogenic factor in Ménétrier's disease. Am J Gastroenterol 1998; 93:1976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeaton P, Frierson HF Jr. Octreotide reduces enteral protein losses in Ménétrier's disease. Am J Gastroenterol 1993; 88:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green BT, Branch MS. Menetrier's disease treated with octreotide long-acting release. Gastrointest Endosc 2004; 60:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunes G, Barosa R, Patita M, et al. Ménétrier's disease : a case of successful treatment using long-acting octreotide. Acta Gastroenterol Belg 2019; 82:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan A, Chhaparia A, Hammami MB, Hachem C. Role of Octreotide in Menetrier's Disease: Case Report and Review of Literature. Cureus 2020; 12:e11515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heurgué-Berlot A, Féron T, Jazeron JF, et al. Ménétrier's disease: Long-term remission with lanreotide. Clin Res Hepatol Gastroenterol 2016; 40:e5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Settle SH, Washington K, Lind C, et al. Chronic treatment of Ménétrier's disease with Erbitux: clinical efficacy and insight into pathophysiology. Clin Gastroenterol Hepatol 2005; 3:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sisson G, Ayis S, Sherwood RA, Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study. Aliment Pharmacol Ther 2014; 40:51.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 34 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18321437" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Menetrier's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3721138" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The morphologic spectrum of large gastric folds: utility of the snare biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3721138" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The morphologic spectrum of large gastric folds: utility of the snare biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368185" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Efficacy of cetuximab in the treatment of Menetrier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1451986" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Possible role of transforming growth factor alpha in the pathogenesis of Ménétrier's disease: supportive evidence form humans and transgenic mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200708" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255847" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Successful use of octreotide to treat Ménétrier's disease: a rare cause of abdominal pain, weight loss, edema, and hypoalbuminemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368184" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Menetrier's disease therapy: rebooting mucosal signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12879076" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8636814" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Ménétrier disease of childhood: role of cytomegalovirus and transforming growth factor alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/199063" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The natural history of hypertrophic gastrophy (Menetrier's disease). Report of a case with 16 year follow-up and review of 120 cases from the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6200022" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Ménétrièr's disease and idiopathic hypertrophic gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7325143" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hyperplastic Gastropathy. Analysis of 50 selected cases from 1955-1980.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1298040" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch Ménétrier Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14184005" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : HYPERTROPHIC HYPERSECRETORY GASTROPATHY. ANALYSIS OF 15 CASES AND A REVIEW OF THE PERTINENT LITERATURE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5316105" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The clinical spectrum of hypertrophic hypersecretory gastropathy. Report of 50 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3933641" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hyperplastic gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5410458" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hypertrophic, hypersecretory protein-losing gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5410456" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Giant thickening of the gastric mucosa with acid hypersecretion and protein-losing gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6124476" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3264139" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ménétrier's disease. A trivalent gastropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2031530" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hyperplastic gastropathy. Clinicopathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7352808" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Spontaneous remission of protein-losing gastropathy associated with Menetrier's disease. A plea for conservative management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15737045" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pathologic quiz case: a 39-year-old woman with nausea, vomiting, diarrhea, and weight loss. Ménétrier disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14215988" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : SPECTRUM OF HYPERTROPHIC GASTROPATHY; GIANT RUGAL FOLDS, POLYPOSIS, AND CARCINOMA OF THE STOMACH--CASE REPORT AND REVIEW OF THE LITERATURE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6886023" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intramucosal carcinoma of the gastric antrum complicating Menetrier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32184187" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Survival Times of Patients With Menetrier's Disease and Risk of Gastric Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28408643" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Gastrin induces parathyroid hormone-like hormone expression in gastric parietal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20844958" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The expression of PTHLH in human gastric mucosa enterochromaffin-like cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1568688" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : [Helicobacter pylori-associated hypertrophic gastritis. Imitation of Ménétrier disease].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8322475" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Giant fold gastritis--a special form of Helicobacter pylori associated gastritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12172358" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The clinical significance of thickened gastric folds found on upper gastrointestinal series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8079936" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9382064" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8200570" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in Ménétrier's disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9083755" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16028444" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17990109" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Helicobacter pylori isolated from a patient with Ménétrier's disease increases hepatocyte growth factor mRNA expression in gastric fibroblasts: comparison with Helicobacter pylori isolated from other gastric diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31304227" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Menetrier's disease (protein-losing gastropathy) in a child with acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16405535" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Endoscopic ultrasonography in patients with large gastric folds at endoscopy and biopsies negative for malignancy: predictors of malignant disease and clinical impact.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12601220" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Giant gastric folds: differential diagnosis at US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16441467" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/872063" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cronkhite-Canada syndrome. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26209527" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Ménétrier Mimicker Complicating Ulcerative Colitis: Proton-Pump Inhibitor-Induced Hyperplastic Polyps.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20926644" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Distinguishing Ménétrier's disease from its mimics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10389370" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Endoscopic ultrasonography in the differential diagnosis of giant gastric folds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8482445" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Menetrier's disease: a form of hypertrophic gastropathy or gastritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12948079" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Ganciclovir treatment in Ménétrier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9455543" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cytomegalovirus gastropathy in a child: resolution after ganciclovir therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9772069" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Helicobacter pylori as a pathogenic factor in Ménétrier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8420282" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Octreotide reduces enteral protein losses in Ménétrier's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15605031" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Menetrier's disease treated with octreotide long-acting release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31566332" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Ménétrier's disease : a case of successful treatment using long-acting octreotide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33354459" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Role of Octreotide in Menetrier's Disease: Case Report and Review of Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26382280" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Ménétrier's disease: Long-term remission with lanreotide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16206497" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Chronic treatment of Ménétrier's disease with Erbitux: clinical efficacy and insight into pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24815298" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
